Table 2. Access to COVID-19 Vaccines in Countries Hosting Completed COVID-19 Vaccine Clinical Trials Categorized by Manufacturer (as of September 7, 2021).
| Manufacturer (vaccine) | Countries that hosted completed COVID-19 vaccine clinical trials, No. | No. (%) | No. (median proportion of population fully vaccinated) [range]a,b | |||
|---|---|---|---|---|---|---|
| Countries that authorized tested vaccine | Countries with doses delivered of tested vaccine | LMICs with completed trials | UMICs with completed trials | HICs with completed trials | ||
| Pfizer-BioNTech (BNT162b2) | 9 | 9 (100.0) | 8 (88.9) | 0 (NA) | 4 (15.3) [0.0-46.2] | 5 (61.7) [51.2-66.5] |
| Moderna (mRNA-1273) | 2 | 2 (100.0) | 2 (100.0) | 0 (NA) | 0 (NA) | 2 (43.3) [40.5-46.1] |
| Janssen–Johnson & Johnson (Ad26.COV2.S) | 10 | 8 (80.0) | 6 (60.0) | 0 (NA) | 6 (2.1) [0.0-7.4] | 4 (3.3) [0.0-19.1] |
| AstraZeneca/Serum Institute of India (AZD1222/Vaxzevria/Covishield)c | 14 | 12 (85.7) | 11 (78.6) | 1 (31.0) | 7 (1.8) [0.0-30.4] | 6 (9.4) [0.0-51.7] |
| Sinopharm (BBIBP-CorV) | 6 | 6 (100.0) | 6 (100.0) | 1 (2.2) | 3 (26.3) [14.3-46.4] | 2 (38.8) [38.2-39.5] |
| Sinovac (CoronaVac) | 5 | 5 (100.0) | 5 (100.0) | 1 (44.3) | 3 (42.3) [28.7-47.3] | 1 (69.7) |
Abbreviations: HICs, high-income countries; LMICs, lower middle–income countries; NA, not applicable; UMICs, upper middle–income countries.
a
Estimate refers to the population within tested countries that is 15 years and older.
b
Data do not account for the population fully vaccinated with any COVID-19 vaccine, only the tested vaccine(s).
c
Because the same efficacy data were submitted for the vaccine Covishield, manufactured by the Serum Institute of India as the vaccine AZD1222 (Vaxzevria) by their common developers, Oxford University and AstraZeneca, this was considered to be a single vaccine for the analyses.